Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its business operations and financial performance. Group 1: Main Business Operations - The company reported a total revenue of 2,253.67 million yuan from its research and experimental development sector in 2024, with a year-on-year growth of 32.41% in the front-end molecular building blocks and tool compounds business, generating 1,499.07 million yuan [1][4] - The product sales revenue in this segment was 1,363.90 million yuan, reflecting a 36.01% increase, while the gross profit margin stood at 63.74% [1][4] - The back-end raw materials and intermediates development business generated 754.61 million yuan, with a modest year-on-year growth of 2.49%, but product sales in this segment saw a decline of 30.45% [1][4] Group 2: Revenue and Profitability Analysis - Domestic and overseas business revenues were 1,391.69 million yuan and 861.99 million yuan respectively, with gross profit margins of 38.82% and 46.8% [1][4] - The company provided a detailed breakdown of its four business segments, including revenue, gross profit margins, and year-on-year changes, indicating a comprehensive analysis of market size and competitive landscape [1][4][6] Group 3: Market Trends and Growth Potential - The global pharmaceutical R&D expenditure is projected to grow at a rate of 4.2% annually, reaching 254 billion USD by 2026, which is expected to positively impact the life sciences reagent market [6][7] - The Chinese research reagent market has expanded from approximately 25 billion yuan in 2018 to about 48 billion yuan in 2022, with a compound annual growth rate of around 18% [6][7] - The global CDMO market is also on a growth trajectory, with expectations to reach 124.3 billion USD by 2025, indicating a robust demand for innovative drug development services [9][10] Group 4: Competitive Positioning - The company has established itself as a competitive player in the life sciences reagent sector, particularly in the molecular building blocks and tool compounds market, which is characterized by strong customization capabilities and a growing customer base [2][4] - The company’s tool compounds business is positioned favorably compared to peers, with higher revenue growth and gross profit margins, reflecting its strong international influence [11][12] - The company’s performance in the generic drug intermediates and raw materials sector aligns with industry trends, with a notable increase in the market for high-end pharmaceutical intermediates [13][14]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-078 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2024 年年度报告信息披露监管问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海皓元医药股份有限公司（以下简称"公司"）于近日收到上海证券交易所下 发的《关于上海皓元医药股份有限公司 2024 年年度报告的信息披露监管问询函》（上 证科创公函【2025】0237 号）以下简称（"《问询函》"）。根据《问询函》的要求， 公司与保荐机构民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）及 年审会计师容诚会计师事务所（特殊普通合伙）（以下简称"容诚"或"年审会计师"） 对《问询函》所提及的事项进行了认真核查，现就《问询函》所涉及问题回复如下： 根据《上海证券交易所科创板股票上市规则》和《公司信息披露暂缓与豁免管理 制度》，公司对本回复中关于客户、供应商名称等事项进行豁免披露处理。本回 ...

回复的专项说明 2024 年年度报告的信息披露监管问询函 关于上海皓元医药股份有限公司 容诚专字[2025]200Z0739 号 中国·北京 容诚会计师事务所(特殊普通合伙) | 问题1.关于主营业务 | | 2 | | --- | --- | --- | | 问题2.关于存货 | | 22 | | 问题3.关于应收账款 | | 35 | | 问题4.关于固定资产和产能建设 | | 43 | | 问题5.关于商誉 | | 51 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于上海皓元医药股份有限公司 2024 年年度报告的信息披露监管问询函 回复的专项说明 容诚专字[2025]200Z0739 号 上海证券交易所： 容诚会计师事务所（特殊普通合伙）（以下简称"年审会计师"、"我们"） 作为上海皓元医药股份有限公司（以下简称" ...

民生证券股份有限公司 关于上海皓元医药股份有限公司 2024 年年度报告的信息披露监管问询函回复的核查意见 上海证券交易所： 根据贵所《关于上海皓元医药股份有限公司 2024 年年度报告的信息披露监 管问询函》（上证科创公函【2025】0237 号，以下简称"《监管问询函》"） 的要求，民生证券股份有限公司（以下简称"民生证券"或"持续督导机构"） 作为上海皓元医药股份有限公司（以下简称"公司"或"皓元医药"）的持续 督导机构，会同公司及相关中介机构，对《监管问询函》所提及的事项进行了 逐项落实，部分信息根据公司的信息披露相关制度的要求进行了豁免，现将 《监管问询函》所涉及问题回复如下： 1 问题 1.关于主营业务 年报显示，（1）公司 2024 年研究和试验发展行业主营业务收入 225,367.38 万元。前端分子砌块和工具化合物业务收入 149,906.68 万元，同比增长 32.41%， 其中产品销售收入 136,390.17 万元，同比增长 36.01%，毛利率 63.74%；技术 服务收入 13,516.5 万元，同比增长 4.52%，毛利率 46.8%。后端原料药和中间 体开发业务收入 75,46 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights that the turning point for research services has arrived, with a focus on companies such as Haoyuan Pharmaceutical, Bidai Pharmaceutical, and Baiaosaitu [1] - The A-share pharmaceutical index has seen a decline of 6.3% this week and an increase of 4.6% year-to-date, underperforming the CSI 300 by 3.9% and outperforming it by 2.3% respectively [4][9] - The report emphasizes the positive impact of recent policies accelerating the development of innovative drugs, which benefits upstream companies involved in research and production [4][18] Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 6.3% this week and increased by 4.6% year-to-date, while the H-share biotechnology index has dropped by 8.2% this week but increased by 48% year-to-date [4][9] - The report notes that the pharmaceutical sector has experienced significant declines, particularly in innovative drugs, with H-shares showing more pronounced drops due to previous high gains [4][9] Research and Development Progress - Recent policies have accelerated the approval processes for innovative drugs, with the FDA reducing NDA approval times from 10-12 months to 1-2 months, and China's CDE shortening IND review times from 60 days to 30 days [18][19] - The report indicates that the demand from the industrial sector is recovering, which will benefit early-stage research suppliers [20] Market Insights - The report suggests focusing on companies that are expected to benefit from the early-stage research demand, mergers and acquisitions, and the commercialization of innovative drugs [19] - Specific companies to watch include Haoyuan Pharmaceutical, Bidai Pharmaceutical, Baiaosaitu, and others in the life sciences service sector [4][19] Investment Strategy - The report recommends a ranking of sub-sectors for investment: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [11] - It highlights specific companies for investment based on growth potential, low valuations, and high dividend yields, particularly in the traditional Chinese medicine sector [11][13]

Core Insights - The article discusses a recent investigation by a well-known private equity firm, Hosheng Asset, into a listed company, Haoyuan Pharmaceutical, highlighting its competitive advantages and growth prospects [1] Company Overview - Haoyuan Pharmaceutical has high barriers to entry in its molecular building block business, with a diverse range of products and strong custom R&D capabilities [1] - The company is projected to achieve a revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7% [1] - Haoyuan's CDMO (Contract Development and Manufacturing Organization) business covers the entire drug development and production process, showcasing core technological, product, and team advantages [1] Production Capabilities - The company has established a production system comprising four key facilities: an API (Active Pharmaceutical Ingredient) factory, a formulation factory, a high-end intermediate factory, and a DC CDMO factory, enabling a three-tiered capacity arrangement [1] - Haoyuan has passed the EU QP audit, ensuring its quality management system and production capabilities meet EU GMP standards, which facilitates further expansion into domestic and international markets [1] Team and Incentives - The company has implemented multiple equity incentive plans targeting core personnel and mid-to-senior management to ensure team stability and creativity [1] Financial Activities - On November 28, 2024, Haoyuan successfully issued convertible bonds, raising 822 million yuan, although it has not yet met the conditions for strong redemption [1]

Group 1 - The company Shanghai Haoyuan Chemexpress Co., Ltd. is issuing convertible bonds amounting to 822.35 million yuan with a maturity of 6 years, starting from December 4, 2024, to November 27, 2030 [3][4][22] - The bond has a face value of 100 yuan per bond, with a tiered interest rate starting at 0.20% in the first year and increasing to 2.00% in the sixth year [5][22] - The initial conversion price for the bonds is set at 40.73 yuan, which may be adjusted based on specific corporate actions such as stock dividends or capital increases [7][9] Group 2 - The company reported a revenue of 227.02 million yuan for the year, reflecting a 20.75% increase compared to the previous year [22] - The total assets of the company reached 550.49 million yuan, marking a 31.31% increase year-over-year [22] - The company has a net profit attributable to shareholders of 0.96 yuan per share, which is a 57.38% increase from the previous year [22] Group 3 - The company focuses on providing CRO and CDMO services for the pharmaceutical and biopharmaceutical industries, with a strong emphasis on small molecule drug development [20][21] - It has established a comprehensive service platform covering the entire drug development process from starting materials to commercial production [21] - The company has approximately 13,000 global partners, showcasing its extensive network and market reach [20]

Group 1 - The company held the sixth meeting of the fourth supervisory board on June 18, 2025, in Shanghai, which was legally convened and attended by all three supervisors [1][2] - The supervisory board voted unanimously to cancel the supervisory board in order to improve the corporate governance structure and comply with the new regulations effective from July 1, 2024, and March 28, 2025 [1][2] - The powers of the supervisory board will be transferred to the audit committee of the board of directors, and related supervisory board regulations will be abolished [1]

上海皓元医药股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688131 证券简称：皓元医药 公告编号：2025-077 转债代码：118051 转债简称：皓元转债 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 7 日 14 点 召开地点：上海市浦东新区张衡路 1999 弄 3 号楼公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 7 日 至2025 年 7 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15: ...